Avammune Therapeutics raises $12 million to advance cancer therapies

Avammune Therapeutics secured $12 million in Series A funding to advance its small molecule immunotherapies targeting cancer and autoimmune disorders. The funding will support clinical trials for AVA-NP-695, an ENPP1 inhibitor showing promise in preclinical models for cancers like osteosarcoma. Avammune's approach focuses on activating the innate immune system, offering a potentially more accessible alternative to existing immuno-oncology treatments.

Most Recent